Immunity-centric biotech firm lands $60m in Series A funding
Immunity-centric biotech firm lands $60m in Series A funding Immunai has secured a total of $80m in funding to develop and promote its efforts to harness machine learning to fuel advancement of novel immunotherapies. New York City- and Tel Aviv-based biotechnology firm Immunai has secured another $60m in Series A funding, bringing the company’s total funding landed to date to more than $80m. Immunai’s technology integrates multi-omic single-cell analytics and mac...
New York United States Kenan Turnacioglu Tel Aviv Based Catalio Capital Management Markets Amp Regulations
Source: outsourcing-pharma.com